Cryptococcosis

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:1546B45.1B45.2B45.3
Who is this for?
Show terms as
2Active trials26Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Cryptococcosis is an infectious disease caused by encapsulated yeast fungi of the genus Cryptococcus, primarily Cryptococcus neoformans and Cryptococcus gattii. It is not a genetic disorder but rather an acquired fungal infection that predominantly affects immunocompromised individuals, particularly those with HIV/AIDS, organ transplant recipients on immunosuppressive therapy, and patients receiving prolonged corticosteroid treatment. However, C. gattii can also cause disease in immunocompetent individuals. The organism is found worldwide in soil, particularly soil contaminated with bird (especially pigeon) droppings, and in association with certain tree species. Cryptococcosis primarily affects the central nervous system and the lungs, though it can disseminate to virtually any organ including the skin, bones, and prostate. The most common and serious manifestation is cryptococcal meningitis (or meningoencephalitis), which presents with headache, fever, neck stiffness, altered mental status, and visual disturbances. Pulmonary cryptococcosis may cause cough, chest pain, and shortness of breath, or may be asymptomatic. Cutaneous involvement can manifest as papules, nodules, or ulcers. Disseminated disease can affect multiple organ systems simultaneously. Treatment depends on the site and severity of infection and the patient's immune status. Cryptococcal meningitis is typically treated with an induction phase of intravenous amphotericin B combined with flucytosine, followed by consolidation and maintenance therapy with fluconazole. Pulmonary or mild-to-moderate disease in immunocompetent patients may be managed with fluconazole alone. In HIV-associated cryptococcosis, antiretroviral therapy is essential but must be carefully timed to avoid immune reconstitution inflammatory syndrome (IRIS). Despite available treatments, cryptococcal meningitis remains a leading cause of death among people living with HIV, particularly in sub-Saharan Africa, with significant global mortality.

Clinical phenotype terms— hover any for plain English:

Nodular pattern on pulmonary HRCTHP:0025392
Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗NORD ↗

FDA & Trial Timeline

6 events
May 2025Platform Trial For Cryptococcal Meningitis

University of Minnesota — PHASE2, PHASE3

TrialRECRUITING
Mar 2025Digital Rewards and Retention in a M-health App

University of Bucharest — NA

TrialNOT YET RECRUITING
Aug 2023Amphotericin B for Non-HIV Cryptococcal Meningitis Patients

Huashan Hospital — PHASE4

TrialENROLLING BY INVITATION
Jun 2019Single Dose Liposomal Amphotericin for Asymptomatic Cryptococcal Antigenemia

Makerere University — PHASE2, PHASE3

TrialRECRUITING
Sep 2009Vicente Ferrer HIV Cohort Study

Rural Development Trust Hospital

TrialRECRUITING
Apr 1993Fungal Infection Susceptibility

National Institute of Allergy and Infectious Diseases (NIAID)

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Cryptococcosis.

2 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

2 recruitingView all trials with filters →
Other2 trials
Vicente Ferrer HIV Cohort Study
Actively Recruiting
PI: Gerardo Alvarez-Uria (Rural Development Trust) · Sites: Battalapalli, Andhra Pradesh
Fungal Infection Susceptibility
Actively Recruiting
PI: Peter R Williamson, M.D. (National Institute of Allergy and Infectious Disea) · Sites: Bethesda, Maryland · Age: 1899 yrs

Specialists

Showing 25 of 26View all specialists →
RM
Radha Rajasingham, MD
MINNEAPOLIS, MN
Specialist
PI on 1 active trial
DP
David B Meya, MBChB, MMed, PhD
Specialist
PI on 1 active trial
DM
David B Meya, MBCHB MMed
Specialist
PI on 1 active trial
GA
Gerardo Alvarez-Uria
Specialist
PI on 1 active trial1 Cryptococcosis publication
DM
David B Meya, MMed
Specialist
PI on 1 active trial
OP
Olivier Lortholary, MD, PhD
Specialist
PI on 5 active trials
EM
Emmanuel Bottieau, MD
Specialist
PI on 2 active trials
PM
Pablo Tebas, MD
PHILADELPHIA, PA
Specialist
PI on 5 active trials
PM
Peter R Williamson, M.D.
CHICAGO, IL
Specialist
PI on 1 active trial
MM
Michael J Vinikoor, MD
CHAPEL HILL, NC
Specialist
PI on 4 active trials
RM
Ranjan K Singh, M.D.
CHICAGO, IL
Specialist
PI on 1 active trial
AM
ANDRES F HENAO, MD
LAWRENCEVILLE, GA
Specialist
PI on 1 active trial1 Cryptococcosis publication
DM
David R Boulware, MD, MPH
MINNEAPOLIS, MN
Specialist
PI on 2 active trials
JM
Joshua Rhein, MD
MINNEAPOLIS, MN
Specialist
PI on 1 active trial
JM
Jeremy Day, MD
HASTINGS, MN
Specialist
PI on 1 active trial
ND
Nguyen V Kinh, Dr
Specialist
PI on 1 active trial
AD
Azure T Makadzange, MD, DPhil
STANFORD, CA
Specialist
PI on 1 active trial
AM
Angela Loyse, MD
Specialist
PI on 1 active trial1 Cryptococcosis publication
ZB
zin win may, B.Pharm
Specialist
PI on 1 active trial
GM
Gregory P Bisson, MD,MSCE
PHILADELPHIA, PA
Specialist
PI on 1 active trial
CF
Chiratidzo E Ndhlovu, MBChB, FRCP
Specialist
PI on 1 active trial
SS
Shmuel Shoham
BALTIMORE, MD
Specialist
PI on 1 active trial
ZL
Zhixin Liang
Specialist
PI on 1 active trial
EN
Elizabeth K Nalintya
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Cryptococcosis.

Search all travel grants →NORD Financial Assistance ↗

Community

Open CryptococcosisForum →

No community posts yet. Be the first to share your experience with Cryptococcosis.

Start the conversation →

Latest news about Cryptococcosis

Disease timeline:

New recruiting trial: Vicente Ferrer HIV Cohort Study

A new clinical trial is recruiting patients for Cryptococcosis

New recruiting trial: Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia

A new clinical trial is recruiting patients for Cryptococcosis

New recruiting trial: Platform Trial For Cryptococcal Meningitis

A new clinical trial is recruiting patients for Cryptococcosis

New recruiting trial: Fungal Infection Susceptibility

A new clinical trial is recruiting patients for Cryptococcosis

New recruiting trial: Single Dose Liposomal Amphotericin for Asymptomatic Cryptococcal Antigenemia

A new clinical trial is recruiting patients for Cryptococcosis

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Cryptococcosis

What is Cryptococcosis?

Cryptococcosis is an infectious disease caused by encapsulated yeast fungi of the genus Cryptococcus, primarily Cryptococcus neoformans and Cryptococcus gattii. It is not a genetic disorder but rather an acquired fungal infection that predominantly affects immunocompromised individuals, particularly those with HIV/AIDS, organ transplant recipients on immunosuppressive therapy, and patients receiving prolonged corticosteroid treatment. However, C. gattii can also cause disease in immunocompetent individuals. The organism is found worldwide in soil, particularly soil contaminated with bird (espe

At what age does Cryptococcosis typically begin?

Typical onset of Cryptococcosis is adult. Age of onset can vary across affected individuals.

Are there clinical trials for Cryptococcosis?

Yes — 2 recruiting clinical trials are currently listed for Cryptococcosis on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Cryptococcosis?

25 specialists and care centers treating Cryptococcosis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.